Rectum Cancer Clinical Trial
Official title:
A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study
Investigating the safety and the activity of Rapamycin, administered before and during preoperative radiotherapy in patients with an operable colorectal carcinoma. The phase I dose escalation study will be performed in three steps (2, 4 and 6 mg). Patients entered in phase II will follow the same tolerable treatment regimen as patients in phase I study.
Treatment regimen Phase I A daily dose of Rapamycin will be taken during 13 days. At step 1 a
dose of 2 mg will be given once a day; at step 2 a dose of 4 mg will be given once a day; at
step 3 a dose of 6 mg will be given once a day.
Preoperative radiotherapy (5x 5 Gy) will be administered at day 8-12, followed by TME-surgery
at day 15.
Phase II A daily dose of 6 mg Rapamycin will be taken for 14 days (unless the optimal dose
found in the phase I study is lower).
Preoperative radiotherapy (5x 5 Gy) will be administered at day 9-15, followed by TME-surgery
7-8 weeks post RT.
Sample size Phase I dose-escalation study Minimum 3 eligible patients per step, maximum 6
eligible patients per step. Phase II A total of 47 patients will be entered in this part of
the study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Completed |
NCT04371198 -
Patient-Derived Organoids for Rectal Cancer
|
N/A | |
| Recruiting |
NCT04916990 -
Improving Care for Rural Patients With Solid Tumors
|
N/A | |
| Active, not recruiting |
NCT05305820 -
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
|
N/A | |
| Recruiting |
NCT03699761 -
The Role of Pelvic Peritonization in Laparoscopic or Robotic Low Anterior Resection
|
N/A | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT03843957 -
Effectiveness and Implementation of mPATH-CRC
|
N/A | |
| Completed |
NCT02423226 -
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
|
Phase 2 | |
| Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
| Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
| Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
| Not yet recruiting |
NCT06066931 -
Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE
|
N/A | |
| Recruiting |
NCT02738359 -
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
|
||
| Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT02458664 -
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
|
N/A | |
| Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
| Recruiting |
NCT05715255 -
Adaptive Symptom Self-Management Immunotherapy Study
|
N/A | |
| Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
| Recruiting |
NCT04405206 -
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
|
||
| Recruiting |
NCT03573791 -
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
|